Drugs / ALTO-101
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06502964 | Jun 2024 → Feb 2026 overdue | schizophrenia | Alto Neuroscience | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ALTO-101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06502964 ↗ |
| Route | Other | “ALTO-101 transdermal delivery system” NCT06502964 ↗ |